Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander".
about
Overview of current immunotherapeutic strategies for gliomaHarnessing immunosurveillance: current developments and future directions in cancer immunotherapyImproving cancer immunotherapy by targeting the STATe of MDSCsNonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunopreventionCancer immunotherapy: how low-level ionizing radiation can play a key role.The efficacy and safety of immunotherapy in patients with advanced NSCLC: a systematic review and meta-analysis.Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in contextAdvances in Immunotherapy for Glioblastoma Multiforme.Vaccine adjuvant uses of poly-IC and derivatives.An update on current and prospective immunotherapies for chronic lymphocytic leukemia.Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab.Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers.Carcinogenesis and therapeutics: the microbiota perspective.Comparative beneficiary effects of immunotherapy against chemotherapy in patients with advanced NSCLC: Meta-analysis and systematic review.The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myeloma.An Anti-Programmed Death-1 Antibody (αPD-1) Fusion Protein That Self-Assembles into a Multivalent and Functional αPD-1 Nanoparticle.Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer.Immunotherapy and gene therapy as novel treatments for cancer.Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity.Immune modulator-induced changes in the gastrointestinal tract.Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.A bifunctional nanomodulator for boosting CpG-mediated cancer immunotherapy.Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions.
P2860
Q26776345-E96CD402-3997-421F-8B4E-7BA2717163FDQ27021570-A67F4779-7F21-42AC-A76E-CF976BFCA985Q28066797-4FB1060A-8267-410A-A359-AD2A5DD39063Q28082487-2E35BAF9-E331-49BE-94A9-B82B23A23209Q30235014-96CCB3CE-EB8A-44FA-878D-D9931A2ADCC6Q33434828-24B5BB41-8209-4290-ABA5-BA54E6CAA431Q37114367-33B36881-CA35-4F87-BA26-003502C80993Q37669352-20BF62CC-C6A8-4027-80ED-4BBF19AFD2A8Q37680966-F322F8FC-1DBF-4EC1-904F-D35911900442Q38259510-B22E5583-EE08-4EE7-BDE1-70129FF47B64Q38445357-6C81CFD7-93FE-4B20-ADB4-3A24F3DC1C9CQ38490909-CA3907F6-28B7-4AEA-8A89-0003E1DDB8F7Q38806038-24F7918C-7D49-4E23-A420-927373E66AD6Q39146396-C6CEF3F5-F5C1-442C-993C-D65E73B5354FQ41143313-B5E3F5B1-89A7-4402-9B39-E2601283114BQ41708947-DAAEC02F-DF2D-4108-8D2D-3D6FBEEAA35DQ41728425-EF64A7C0-96C0-4623-93F7-F16D9AD8BD7EQ42369857-D89B2997-B987-46F9-9F7F-26BF84A0B58DQ45875535-CDA0F780-F1CD-446D-8FF1-840096735370Q47100447-5316238D-86BA-47C2-BB24-7462F0063F86Q48362425-A854B0EB-9DAD-4F94-9B8B-29FE872FA748Q49315568-4BE50E61-36EA-4873-8B44-61B78C216315Q50072990-716A3792-E899-45AA-852F-EAF2BD22810CQ53120477-265BB68D-1096-4F39-881C-68447F7ACAE0
P2860
Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander".
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 March 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Immune checkpoint blockade in ...... st as an "innocent bystander".
@en
Immune checkpoint blockade in ...... st as an "innocent bystander".
@nl
type
label
Immune checkpoint blockade in ...... st as an "innocent bystander".
@en
Immune checkpoint blockade in ...... st as an "innocent bystander".
@nl
prefLabel
Immune checkpoint blockade in ...... st as an "innocent bystander".
@en
Immune checkpoint blockade in ...... st as an "innocent bystander".
@nl
P2093
P2860
P356
P1433
P1476
Immune checkpoint blockade in ...... ost as an "innocent bystander"
@en
P2093
Angela Esposito
Aron Goldhirsch
Carmen Criscitiello
Lucia Gelao
P2860
P304
P356
10.3390/TOXINS6030914
P5008
P577
2014-03-03T00:00:00Z